AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35839426 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconsolidation immunotherapy including dinutuximab, granulocyte-macrophage colony-stimulating factor, and interleukin-2
Number of subjects: 1183
Study 35839786 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel
Number of subjects: 61
Study 35840448 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using near-infrared (NIR) fluorescence imaging with indocyanine green dye during ALND
Number of subjects: 119
Study 35840448 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) using near-infrared (NIR) fluorescence imaging
Number of subjects: 119
Study 35840506 — intervention group
Group type: EXPERIMENTAL
Intervention: Low second trimester resting energy expenditure (REE)
Number of subjects: 26
Study 35840506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass, energy intake (EI), physical activity (PA), and REE
Number of subjects: 26
Study 35840506 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy intake (EI)
Number of subjects: 26
Study 35840506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass and physical activity (PA)
Number of subjects: 26
Study 35840541 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 158
Study 35840541 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 158
Study 35840573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amcenestrant 20-600 mg QD
Number of subjects: 16
Study 35840753 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche PD Mobile Application v2
Number of subjects: 316
Study 35840898 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Service Hub (GSH) programme
Number of subjects: 0
Study 35840898 — intervention group
Group type: COMPARATOR
Intervention: Propensity score-matched comparator group
Number of subjects: 0
Study 35840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab (4 injections starting on the same day and on weeks 4, 7, and 10)
Number of subjects: 25
Study 35840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course preoperative radiotherapy (5 Gy × 5 days) and pembrolizumab
Number of subjects: 25
Study 35840942 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy students
Number of subjects: 1154
Study 35840942 — intervention group
Group type: COMPARATOR
Intervention: All other NMAHP students
Number of subjects: 1154
Study 35840949 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV self-testing as the primary screening test
Number of subjects: 0
Study 35841019 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Decision Making-Renal Supportive Care (SDM-RSC) intervention
Number of subjects: 60
Study 35841019 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) conversations
Number of subjects: 60
Study 35841032 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm function assessment using ultrasound, magnetic stimulation, and balloon catheter-based recordings in patients with dyspnea on exertion.
Number of subjects: 10
Study 35841032 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (not specified how many or their characteristics).
Number of subjects: 10
Study 35841038 — intervention group
Group type: EXPERIMENTAL
Intervention: VCP disease patients with confirmed VCP variants
Number of subjects: 106
Study 35841049 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-lead Holter ECGs
Number of subjects: 20
Study 35841049 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA Task Load Index
Number of subjects: 20
Study 35841053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseason assessments of eccentric hamstring strength, on-field sprinting biomechanics, and muscle-tendon volumes using MRI.
Number of subjects: 1200
Study 35841053 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessments and MRI examinations post-injury and after rehabilitation.
Number of subjects: 1200
Study 35841086 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized psychomotor assessment
Number of subjects: 25
Study 35841307 — intervention group
Group type: EXPERIMENTAL
Intervention: Local therapy (initial primary surgery in 7 cases)
Number of subjects: 11
Study 35841307 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic therapy (5 patients)
Number of subjects: 11
Study 35841307 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 11
Study 35841429 — intervention group
Group type: EXPERIMENTAL
Intervention: YMD-CHO
Number of subjects: 8
Study 35841429 — intervention group
Group type: EXPERIMENTAL
Intervention: YMD-F
Number of subjects: 8
Study 35841429 — intervention group
Group type: COMPARATOR
Intervention: Control-CHO
Number of subjects: 8
Study 35841456 — intervention group
Group type: EXPERIMENTAL
Intervention: Button battery ingestion
Number of subjects: 415
Study 35841456 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms related to esophageal impaction
Number of subjects: 415
Study 35841456 — intervention group
Group type: EXPERIMENTAL
Intervention: Button batteries > 15 mm
Number of subjects: 415
Study 35841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 1 (metachronous mHSPC) - 35% of patients developed metastases before becoming castration resistant
Number of subjects: 2859
Study 35841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 2 - 10% of patients developed castration resistance before metastases
Number of subjects: 2859
Study 35841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 3 - 27% of patients developed metastases and castration resistance within 4 months
Number of subjects: 2859
Study 35841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis sequence 4 (de novo mHSPC) - 28% of patients
Number of subjects: 2859
Study 35842005 — intervention group
Group type: EXPERIMENTAL
Intervention: High lipid content segments
Number of subjects: 1269
Study 35842005 — intervention group
Group type: EXPERIMENTAL
Intervention: Segments with increasing lipidic content and plaque burden
Number of subjects: 1269
Study 35842005 — intervention group
Group type: EXPERIMENTAL
Intervention: Segments with maxLCBI
Number of subjects: 1269
Study 35842202 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliac branch endoprosthesis (IBE) device implantation
Number of subjects: 63
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV incident infections
Number of subjects: 6322
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59)
Number of subjects: 6322
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16/18
Number of subjects: 6322
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31/33/45/52/58
Number of subjects: 6322
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable types
Number of subjects: 6322
Study 35842229 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV prevalences
Number of subjects: 6322
Study 35842320 — intervention group
Group type: EXPERIMENTAL
Intervention: NRN Follow-up Study Group interventions
Number of subjects: 0
Study 35842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive leg raising
Number of subjects: 270
Study 35842352 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 270
Study 35842563 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS) with Sonazoid
Number of subjects: 26
Study 35842567 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib (200 or 240 mg/m)
Number of subjects: 77
Study 35842567 — intervention group
Group type: COMPARATOR
Intervention: Trilaciclib (200 or 240 mg/m) with rifampin
Number of subjects: 77
Study 35842567 — intervention group
Group type: COMPARATOR
Intervention: Trilaciclib (200 or 240 mg/m) with itraconazole
Number of subjects: 77
Study 35843046 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solutions (Plasma Lye 148)
Number of subjects: 10490
Study 35843046 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 10490
Study 35843046 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced solutions (Plasma Lye 148) in traumatic brain injury patients
Number of subjects: 10490
Study 35843046 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline in traumatic brain injury patients
Number of subjects: 10490
Study 35843096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum rheology assessment using Rheomuco® rheometer
Number of subjects: 48
Study 35843096 — intervention group
Group type: COMPARATOR
Intervention: Sputum rheology assessment in asthma patients
Number of subjects: 48
Study 35843096 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of rheology with mucin concentrations
Number of subjects: 48
Study 35843439 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 21
Study 35843546 — intervention group
Group type: EXPERIMENTAL
Intervention: AB680 (CD73 inhibitor)
Number of subjects: 0
Study 35843546 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib (CDK4/6 inhibitor)
Number of subjects: 0
Study 35843546 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AB680 and palbociclib
Number of subjects: 0
Study 35843549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid recovery protocol (RP) with local infiltration of levo-bupivacaine and supervised ambulation 4-6 hours after surgery
Number of subjects: 175
Study 35843549 — intervention group
Group type: COMPARATOR
Intervention: Control group with femoral nerve block with levo-bupivacaine and ambulation after drain removal
Number of subjects: 175
Study 35843549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid recovery protocol (RP)
Number of subjects: 175
Study 35843549 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study 35843615 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly sensitive troponin assay
Number of subjects: 1500
Study 35843615 — intervention group
Group type: COMPARATOR
Intervention: Local troponin testing results
Number of subjects: 1500
Study 35843615 — intervention group
Group type: COMPARATOR
Intervention: Clinical grounds diagnosis
Number of subjects: 1500
Study 35843739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib 3 or 4 mg, Serabelisib 200 mg on days 2-4, 9-11, 16-18 and 23-25 with Paclitaxel 80 mg/m2 on days 1, 8 and 15 every 28 days
Number of subjects: 19
Study 35843739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib, Serabelisib, and Paclitaxel
Number of subjects: 19
Study 35843746 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anaemia
Number of subjects: 2983
Study 35843943 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation (iTBS)
Number of subjects: 10
Study 35843943 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation
Number of subjects: 10
Study 35844014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow concentrate (BMC) injections
Number of subjects: 12780
Study 35844029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucitanib (5-30 mg daily doses)
Number of subjects: 403
Study 35844029 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucitanib formulation (film-coated tablet or hard gelatin capsule)
Number of subjects: 403
Study 35844029 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant medications (CYP3A4 inhibitors/inducers, CYP2C8 or P-glycoprotein inhibitors, proton pump inhibitors)
Number of subjects: 403
Study 35844029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing clinical study of lucitanib
Number of subjects: 403
Study 35844042 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 748
Study 35844168 — intervention group
Group type: COMPARATOR
Intervention: OROS-MPH (osmotic-release oral system methylphenidate)
Number of subjects: 94
Study 35844168 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 with risperidone and usual anti-seizure medication (ASM)
Number of subjects: 94
Study 35844232 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroepo
Number of subjects: 26
Study 35844232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 35844693 — intervention group
Group type: EXPERIMENTAL
Intervention: SKY92 molecular signature analysis
Number of subjects: 147
Study 35844773 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ENERGI-F703 gel applied twice daily for 12 weeks or until complete ulcer closure
Number of subjects: 0
Study 35844773 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel applied twice daily for 12 weeks or until complete ulcer closure
Number of subjects: 0
Study 35845005 — intervention group
Group type: EXPERIMENTAL
Intervention: VTd-mod (100 mg daily thalidomide)
Number of subjects: 0
Study 35845005 — intervention group
Group type: COMPARATOR
Intervention: VTd-label (escalating thalidomide dose up to 200 mg daily)
Number of subjects: 0
Study 35845063 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Diastolic Dysfunction (LVDD)
Number of subjects: 54
Study 35845063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score (LUSS)
Number of subjects: 54
Study 35845063 — intervention group
Group type: EXPERIMENTAL
Intervention: LVDD
Number of subjects: 54
Study 35845292 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to venetoclax after progression on venetoclax monotherapy
Number of subjects: 10
Study 35845461 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate of new suicide attempts during 3 months of follow-up
Number of subjects: 200
Study 35845461 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-demographic, clinical and biological assessments including blood and hair cortisol levels, plasma pro- and mature BDNF isoforms proportion
Number of subjects: 200
Study 35845530 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment for LARC
Number of subjects: 302
Study 35845797 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies synbiotic supplement (once daily for 12 weeks)
Number of subjects: 61
Study 35845797 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 61
Study 35845810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeDiet) group
Number of subjects: 78
Study 35845810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 35845857 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision prevention materials incorporating genetic testing
Number of subjects: 920
Study 35845857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 920
Study 35846031 — intervention group
Group type: EXPERIMENTAL
Intervention: Avadomide (CC-122) 3 mg/day 5 days on/2 days off plus rituximab 375 mg/m2
Number of subjects: 0
Study 35846039 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model with COO subgroups
Number of subjects: 1263
Study 35846039 — intervention group
Group type: COMPARATOR
Intervention: International prognostic index (IPI)
Number of subjects: 1263
Study 35846096 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selinexor plus low-dose dexamethasone (Sel-dex)
Number of subjects: 186
Study 35846096 — intervention group
Group type: COMPARATOR
Intervention: Other available therapies (control group)
Number of subjects: 186
Study 35846097 — intervention group
Group type: EXPERIMENTAL
Intervention: VTd-mod (bortezomib, thalidomide 100 mg/day, dexamethasone)
Number of subjects: 0
Study 35846097 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VTd (bortezomib, thalidomide, dexamethasone with daratumumab)
Number of subjects: 0
Study 35846097 — intervention group
Group type: COMPARATOR
Intervention: VTd-label (bortezomib, thalidomide 200 mg/day, dexamethasone)
Number of subjects: 0
Study 35846215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel)
Number of subjects: 0
Study 35846215 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of treatment (PCT)
Number of subjects: 0
Study 35846221 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-122 plus rituximab
Number of subjects: 106
Study 35846221 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-223 and CC-292 combinations
Number of subjects: 106
Study 35846221 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-122
Number of subjects: 106
Study 35846221 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment arms
Number of subjects: 106
Study 35846221 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 106
Study 35846226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 125 mg
Number of subjects: 346
Study 35846226 — intervention group
Group type: EXPERIMENTAL
Intervention: Lebrikizumab 37.5 mg
Number of subjects: 346
Study 35846226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 35846272 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperaldosteronism
Number of subjects: 57
Study 35846333 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods (random forest, RF)
Number of subjects: 929
Study 35846333 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning methods (support vector machine, SVM)
Number of subjects: 929
Study 35846333 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation using RF method
Number of subjects: 929
Study 35846333 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation using SVM method
Number of subjects: 929
Study 35847080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirschsprung-associated enterocolitis (HAEC) group
Number of subjects: 103
Study 35847080 — intervention group
Group type: COMPARATOR
Intervention: Hirschsprung's disease without enterocolitis (HD) group
Number of subjects: 103
Study 35847221 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 0
Study 35847524 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote visits via phone
Number of subjects: 45
Study 35847524 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote visits via videochat
Number of subjects: 45
Study 35847524 — intervention group
Group type: COMPARATOR
Intervention: Conventional outpatient visits
Number of subjects: 45
Study 35847524 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort satisfaction (physician satisfaction)
Number of subjects: 45
Study 35847524 — intervention group
Group type: COMPARATOR
Intervention: Conventional visits (physician satisfaction)
Number of subjects: 45
Study 35847524 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone visits (physician satisfaction)
Number of subjects: 45
Study 35847524 — intervention group
Group type: EXPERIMENTAL
Intervention: Video visits (physician satisfaction)
Number of subjects: 45
Study 35847807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered cuff tracheal tube
Number of subjects: 80
Study 35847807 — intervention group
Group type: COMPARATOR
Intervention: Conventional cylindrical high-volume low-pressure cuff (control)
Number of subjects: 80
Study 35847877 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium68-fibroblast-activation protein inhibitor
Number of subjects: 25
Study 35848424 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35848462 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35848614 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIKOK-19 T-cell therapy
Number of subjects: 9
Study 35848622 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline treatment
Number of subjects: 96
Study 35848990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% pilocarpine ophthalmic solution eye drops
Number of subjects: 0
Study 35848990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35848991 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCL system after temporary target (TT) use
Number of subjects: 60
Study 35848991 — intervention group
Group type: COMPARATOR
Intervention: HCL system after temporary target (TT) use
Number of subjects: 60
Study 35848991 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCL system during non-TT periods
Number of subjects: 60
Study 35848991 — intervention group
Group type: COMPARATOR
Intervention: HCL system during non-TT periods
Number of subjects: 60
Study 35849186 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal Ulna Locking Plate (DUL)
Number of subjects: 20
Study 35849430 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-driven process for identifying unpaid caregivers
Number of subjects: 12212
Study 35849430 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans characteristics associated with having unpaid caregivers
Number of subjects: 12212
Study 35849756 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 76
Study 35849756 — intervention group
Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 76
Study 35849791 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus Gilteritinib
Number of subjects: 61
Study 35850123 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exposure prophylaxis (PEP) with rifampicin
Number of subjects: 1199
Study 35850123 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 1199
Study 35850444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline plasma L-arginine (ARG) levels (<42 μM)
Number of subjects: 373
Study 35850444 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline plasma L-arginine (ARG) levels
Number of subjects: 373
Study 35850444 — intervention group
Group type: EXPERIMENTAL
Intervention: Low baseline plasma L-arginine (ARG) levels
Number of subjects: 373
Study 35850660 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS Test
Number of subjects: 10000
Study 35850705 — intervention group
Group type: EXPERIMENTAL
Intervention: EVD based CSF-Hb
Number of subjects: 250
Study 35850705 — intervention group
Group type: EXPERIMENTAL
Intervention: LD based CSF-Hb
Number of subjects: 250
Study 35850705 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-Hb
Number of subjects: 250
Study 35850765 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes (preDM)
Number of subjects: 544